Glaucoma
Welcome,         Profile    Billing    Logout  
 90 Companies   65 Products   65 Products   50 Mechanisms of Action   804 Trials   63193 News 


«12...7891011121314151617...702703»
  • ||||||||||  Journal, Real-world evidence, Real-world:  Risk Factors for Developing Neovascular Glaucoma in Central Retinal Vein Occlusion: Two-Year Real-World Study. (Pubmed Central) -  Mar 12, 2025   
    Patients presenting with CRVO who have comorbidities such as DM, older age, and worse VA warrant closer attention and intensive follow-up for the development of NVG. Additionally, the statistical analysis indicated that the presence of macular edema, increased central macular thickness, CV events, history of glaucoma, and early PRP within 3?months had no significant impact on the likelihood of developing NVG.
  • ||||||||||  Retrospective data, Journal:  Safety of intravitreal injections with the mobile laminar airflow device Operio after more than 10.000 injections. (Pubmed Central) -  Mar 12, 2025   
    Additionally, the statistical analysis indicated that the presence of macular edema, increased central macular thickness, CV events, history of glaucoma, and early PRP within 3?months had no significant impact on the likelihood of developing NVG. The OCR equipped with Operio was easy to set up, safe regarding all IVI-related complications, first and foremost endophthalmitis, helpful in improving the management of IVIS, and allowed us to decongest the operating room for more complex surgeries.
  • ||||||||||  Clinical, Journal:  Fractal Dimension Analysis of Peripapillary Microvasculature in Primary Congenital Glaucoma. (Pubmed Central) -  Mar 12, 2025   
    Our results provide additional evidence supporting GATT and PHACOGATT as viable options for the treatment of medically uncontrolled glaucoma patients requiring low and stable IOPs. PCG was associated with lower vascular parameters in the vitreo-retina (large retinal vessels) and ILM-NFL (RPC) layers as detected by OCTA FD.
  • ||||||||||  Journal:  Visual Field Progression in Glaucoma During COVID-19. (Pubmed Central) -  Mar 12, 2025   
    PCG was associated with lower vascular parameters in the vitreo-retina (large retinal vessels) and ILM-NFL (RPC) layers as detected by OCTA FD. In patients with glaucoma on follow up, higher rates and proportions of visual field progression were found post the COVID-19 pandemic compared to pre pandemic.
  • ||||||||||  Retrospective data, Journal:  Risk factors and protective strategies for hypotony following preserflo microshunt implantation. (Pubmed Central) -  Mar 12, 2025   
    Importantly, intraluminal suture stenting mitigated the risk of hypotony without compromising the short-term surgical outcomes. These findings emphasize the need for careful patient selection and the potential of intraluminal suture stenting as an effective intraoperative strategy to improve the safety and outcomes of PMS implantation.
  • ||||||||||  Journal:  Unusual fundus lesion in mosaic neurofibromatosis type 2. (Pubmed Central) -  Mar 12, 2025   
    Histopathology showed an optic nerve sheath meningioma with intraocular extension. Although ocular abnormalities in NF2 are a relatively rare finding in young children, this case shows that an optic nerve sheath meningioma can show intraocular extension and should be considered in the differential diagnosis for an intraocular mass.
  • ||||||||||  Journal, Monotherapy:  Visual outcomes and adherence challenges in proliferative diabetic retinopathy anti-VEGF monotherapy in the clinical practice setting. (Pubmed Central) -  Mar 12, 2025   
    Although ocular abnormalities in NF2 are a relatively rare finding in young children, this case shows that an optic nerve sheath meningioma can show intraocular extension and should be considered in the differential diagnosis for an intraocular mass. The frequent follow-up appointments and repeat treatments necessary for anti-VEGF monotherapy in PDR can pose challenges to maintaining the required schedule and can result in worse visual acuity outcomes and increased ocular complications.
  • ||||||||||  Journal:  Outcomes of Persistent Exudative Retinal Detachments Following Proton Beam Irradiation for Choroidal Melanoma. (Pubmed Central) -  Mar 12, 2025   
    The frequent follow-up appointments and repeat treatments necessary for anti-VEGF monotherapy in PDR can pose challenges to maintaining the required schedule and can result in worse visual acuity outcomes and increased ocular complications. Choroidal melanoma with a large ERD can be successfully treated with conservative or surgical management after proton beam radiation therapy.
  • ||||||||||  Journal:  Spatial-aware Transformer-GRU Framework for Enhanced Glaucoma Diagnosis from 3D OCT Imaging. (Pubmed Central) -  Mar 12, 2025   
    Experimental results on a large dataset demonstrate the superior performance of the proposed method over state-of-the-art ones, achieving an F1-score of 93.01%, Matthews Correlation Coefficient (MCC) of 69.33%, and AUC of 94.20%. The framework's ability to leverage the valuable information in 3D OCT data holds significant potential for enhancing clinical decision support systems and improving patient outcomes in glaucoma management.
  • ||||||||||  Preclinical, Journal:  Measurement of Aqueous Humor Viscosity in an Experimental Rabbit Model With Corneal Neovascularization. (Pubmed Central) -  Mar 12, 2025   
    AH viscosity positively correlated with VEGF-A concentration, particularly in CNV-induced eyes with elevated VEGF-A levels. The correlation between VEGF-A levels and AH viscosity in an experimental model of corneal neovascularization suggests that AH viscosity could serve as a biomarker for predicting IOP or surgical outcomes in conditions like neovascular glaucoma.
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Persistence of Glaucoma Patients With Web-Browser-Based Visual Field Test (clinicaltrials.gov) -  Mar 12, 2025   
    P=N/A,  N=13, Terminated, 
    Independently of longer axial length, thinner choroidal thickness is a factor associated with lower BCVA in myopic eyes, including eyes with MMD stage 1. N=50 --> 13 | Trial completion date: Dec 2025 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Mar 2025; Testing software discontinued by vendor.
  • ||||||||||  brimonidine tartrate / Generic mfg.
    Journal:  Are Alpha-2 Adrenergic Agonists Being Used in Infants? (Pubmed Central) -  Mar 10, 2025   
    Ophthalmologists should be aware of these potential risks. Further, more rigorous warnings should be in place to prevent unintentional exposure of infants to brimonidine.
  • ||||||||||  Preclinical, Journal:  Astrocytes in the mouse brain respond bilaterally to unilateral retinal neurodegeneration. (Pubmed Central) -  Mar 10, 2025   
    A subpopulation of these astrocytes in contact with large descending blood vessels were immunopositive for LCN2, a marker associated with astrocyte reactivity. Together, these data suggest that even early stages of unilateral glaucoma have broad impacts on the health of astrocytes across both hemispheres of the brain, implying a glial mechanism behind neurodegenerative comorbidity in glaucoma.
  • ||||||||||  Journal:  Re: Lee et (Pubmed Central) -  Mar 9, 2025   
    Patient-reported outcomes were favorable, and the safety profile of the implant was acceptable. No abstract available
  • ||||||||||  Journal:  Re: Lee et (Pubmed Central) -  Mar 9, 2025   
    No abstract available No abstract available
  • ||||||||||  Retrospective data, Journal:  Shifting Paradigms in Glaucoma Management: A Retrospective Analysis from 2013 to 2023. (Pubmed Central) -  Mar 9, 2025   
    Among glaucoma drainage devices (GDDs), Ahmed Glaucoma Valve usage declined from 94.25% (246/261) to 61.66% (193/313), while the Ex-Press device was phased out, and XEN Gel Stent (MIGS) usage rose to 38.34% (120/313). Glaucoma surgical management at the Eye & ENT Hospital of Fudan University has evolved significantly over the past decade, with a notable shift towards minimally invasive procedures and personalized treatment strategies.
  • ||||||||||  Review, Journal:  Ocular manifestations secondary to cocaine abuse - A reviewRunning head: Ocular Complications of Cocaine Abuse. (Pubmed Central) -  Mar 9, 2025   
    By categorizing the findings based on the anatomical location and type of pathology-orbital, corneal, retinal, neuro-ophthalmic, glaucoma-related, and uveal manifestations-we aim to provide a detailed overview that aids in early diagnosis and effective management of ocular disease secondary to cocaine use. Our review highlights the importance of awareness among clinicians, showcasing the wide range of ocular pathology to improve patient outcomes and prevent long-term ocular damage after cocaine abuse.
  • ||||||||||  Review, Journal:  Heme-thiolate monooxygenase cytochrome P450 1B1, an old dog with many new tricks. (Pubmed Central) -  Mar 9, 2025   
    Dysregulation or genetic mutations of the gene encoding this enzyme can lead to health complications and may increase the risk of diseases such as cancer and liver fibrosis. In this review, we summarize recent preclinical and clinical evidence that underscores the potential of CYP1B1 as a therapeutic target.
  • ||||||||||  Review, Journal:  From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases. (Pubmed Central) -  Mar 9, 2025   
    This review summarizes the application strategies and delivery methods of CRISPR/Cas, discusses recent progress in CRISPR/Cas-based disease models and therapies, and provides an overview of the landscape of clinical trials. Current obstacles and future directions regarding the bench-to-bedside transition are also discussed.
  • ||||||||||  Reimbursement, US reimbursement, Journal, Medicare:  Associations Between Socioeconomic Factors and Neovascular Glaucoma in a United States Medicare Population. (Pubmed Central) -  Mar 7, 2025   
    In the 2019 CA Medicare population, associations between high SVI-SES, DMME, and increased prevalence of NVG were weakened after adjustment for demographic factors. Further studies are needed to assess for differential management of retinal ischemia in at-risk individuals based on age, sex, and race and ethnicity, independent of SES.
  • ||||||||||  Enrollment open, Trial primary completion date:  GATT Versus Canaloplasty (GVC) (clinicaltrials.gov) -  Mar 7, 2025   
    P=N/A,  N=100, Recruiting, 
    However, further research is needed to establish causality. Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jun 2025